• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

海绵体内注射血管活性药物治疗动脉性阳痿后阴茎血栓素B2和前列环素的变化

The change of penile blood thromboxane B2 and prostacyclin after intracavernous injection of vasoactive drugs for the treatment of arteriogenic impotence.

作者信息

Lin J S, Chang W C, Lui S M

机构信息

Department of Urology, National Cheng Kung University Medical College, Tainan, Taiwan, R.O.C.

出版信息

Proc Natl Sci Counc Repub China B. 1994 Jan;18(1):12-6.

PMID:8029369
Abstract

Penile hypercoagulability during erection may predispose to aging vascular changes and, eventually, arteriogenic impotence. The relationship of penile blood thromboxane B2 and 6-keto-prostaglandin F1 alpha in both psychogenically and arteriogenically impotent patients after intracavernosal treatment with papaverine plus phentolamine or prostaglandin E1 was evaluated. No significant change in penile blood thromboxane B2 was observed with treatment of these vasoactive drugs. On the other hand, penile blood 6-keto-prostaglandin F1 alpha was significantly increased with the injection of 30 mg of papaverine plus 0.5 mg of phentolamine, and of 20 micrograms prostaglandin E1. Furthermore, the prostacyclin-to-thromboxane A2 ratio for the patient who received papaverine plus phentolamine was significantly lower than that for the same individual receiving prostaglandin E1. Our preliminary findings suggest that penile blood prostacyclin may participate in the pathogenesis of arteriogenic impotence and priapism.

摘要

勃起过程中阴茎的高凝状态可能会导致血管老化改变,并最终引发动脉性阳痿。我们评估了在精神性和动脉性阳痿患者中,经海绵体内注射罂粟碱加酚妥拉明或前列腺素E1治疗后,阴茎血液中血栓素B2和6-酮-前列腺素F1α的关系。使用这些血管活性药物治疗后,未观察到阴茎血液中血栓素B2有显著变化。另一方面,注射30毫克罂粟碱加0.5毫克酚妥拉明以及20微克前列腺素E1后,阴茎血液中6-酮-前列腺素F1α显著增加。此外,接受罂粟碱加酚妥拉明治疗的患者,其前列环素与血栓素A2的比值显著低于接受前列腺素E1治疗的同一患者。我们的初步研究结果表明,阴茎血液中的前列环素可能参与动脉性阳痿和阴茎异常勃起的发病机制。

相似文献

1
The change of penile blood thromboxane B2 and prostacyclin after intracavernous injection of vasoactive drugs for the treatment of arteriogenic impotence.海绵体内注射血管活性药物治疗动脉性阳痿后阴茎血栓素B2和前列环素的变化
Proc Natl Sci Counc Repub China B. 1994 Jan;18(1):12-6.
2
The change of urinary 11-dehydro-thromboxane B2 and 2,3-dinor-6-keto-prostaglandin F1 alpha in arteriogenic impotence.动脉性阳痿患者尿中11-脱氢血栓素B2和2,3-二去甲-6-酮-前列腺素F1α的变化
J Urol. 1992 Aug;148(2 Pt 1):311-3. doi: 10.1016/s0022-5347(17)36581-3.
3
Prostaglandin E1 versus phentolamine/papaverine for the treatment of erectile impotence: a double-blind comparison.前列腺素E1与酚妥拉明/罂粟碱治疗勃起功能障碍的双盲比较
J Urol. 1989 Mar;141(3):549-50. doi: 10.1016/s0022-5347(17)40889-5.
4
[Intracavernous injection of vasoactive drugs for treating erectile impotence].[海绵体内注射血管活性药物治疗勃起功能障碍]
Hinyokika Kiyo. 1988 Feb;34(2):301-4.
5
Intracavernous pharmacotherapy for impotence: selection of appropriate agent and dose.阴茎海绵体内药物治疗勃起功能障碍:合适药物及剂量的选择。
J Urol. 1993 May;149(5 Pt 2):1288-90. doi: 10.1016/s0022-5347(17)36370-x.
6
[Intracavernous pharmacotherapy for treatment and evaluation of impotence].[阴茎海绵体内药物治疗用于阳痿的治疗与评估]
Harefuah. 1991 Oct;121(7-8):223-5.
7
Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction.前列腺素E1联合酚妥拉明治疗勃起功能障碍
Int J Impot Res. 1996 Mar;8(1):5-7.
8
Papaverine-phentolamine and prostaglandin E1 versus papaverine-phentolamine alone for intracorporeal injection therapy: a clinical double-blind study.罂粟碱-酚妥拉明与前列腺素E1联合应用与单独应用罂粟碱-酚妥拉明用于体内注射治疗的临床双盲研究。
J Urol. 1995 Sep;154(3):1017-9.
9
Prostacyclin-to-thromboxane A2 ratio in arteriogenic impotence.动脉生成性阳痿中前列环素与血栓素A2的比值
J Urol. 1990 Dec;144(6):1373-5. doi: 10.1016/s0022-5347(17)39745-8.
10
[Clinical evaluation of intracavernous self-injection of vasoactive drugs for impotence: a long-term follow-up observation].[海绵体内注射血管活性药物治疗阳痿的临床评估:长期随访观察]
Hinyokika Kiyo. 1994 Jan;40(1):37-41.